SAMONE WEATHERLY: Open Payments
NPI 1942828678 · COMMERCE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$721 in 39 payments from 16 companies in 2025. Trend: 2023 $412 · 2024 $517 · 2025 $721
Food & beverage: $721
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $204 |
| GlaxoSmithKline, LLC. | 6 | $109 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Novo Nordisk Inc | 4 | $70 |
| ABIOMED | 1 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Viatris Specialty LLC | 1 | $20 |
| Exact Sciences Corporation | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
Products named: VRAYLAR, TRELEGY ELLIPTA, AUSTEDO XR, Ozempic, CAPLYTA, LINZESS, BREZTRI, YUPELRI.
Industry payments across TX — which companies pay providers there.
